Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis
Leuk Lymphoma
.
2020 Mar;61(3):737-740.
doi: 10.1080/10428194.2019.1683735.
Epub 2019 Nov 11.
Authors
Marco Cerrano
1
2
,
Valérie Seegers
3
,
Emmanuel Raffoux
1
,
Florence Rabian
1
,
Marie Sébert
4
,
Raphael Itzykson
1
,
Virginie Lemiale
5
,
Lionel Adès
4
,
Nicolas Boissel
6
,
Hervé Dombret
1
,
Elie Azoulay
5
,
Etienne Lengliné
1
Affiliations
1
Hématologie Adulte, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France.
2
Department of Oncology, Division of Hematology, AOU Città Della Salute e Della Scienza di Torino, Turin, Italy.
3
Institut de Cancérologie de l'Ouest - Paul Papin, Direction de la Recherche clinique et de l'innovation, Angers, France.
4
Hématologie Seniors, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France.
5
Medical Intensive Care Unit, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France.
6
Hématologie Adolescents et Jeunes Adultes, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France.
PMID:
31710255
DOI:
10.1080/10428194.2019.1683735
No abstract available
Publication types
Letter
MeSH terms
Humans
Hydroxyurea* / adverse effects
Leukemia, Myeloid, Acute* / complications
Leukemia, Myeloid, Acute* / drug therapy
Leukocytosis / chemically induced
Substances
Hydroxyurea